Brett A. French, Ph.D.

Professor, Biomedical Engineering Medicine/Cardiovascular Medicine Dept. of Radiology

Contact

name@university.edu

Mobile

(410) 555-1234

Office

(410) 555-1234

Location

MR5 Building, Room 1219

Lab

MR5 Building, Rooms 1205, 1217 and 1219

P.O. Box 800759
Charlottesville, Virginia 22908

Google Scholar Page Research Summary

About

Brent A. French combines advanced methods of targeted drug and gene delivery with biomedical imaging in vivo to explore novel targets and treatment strategies in cardiovascular disease and cancer. Research interests of the Molecular Bioengineering Lab focus on developing new, more effective strategies for treating and preventing human disease. In parallel, we develop novel diagnostic imaging methods to better understand the progression/regression of disease and the impact of novel therapies on specific disease targets. A highly-collaborative, interdisciplinary approach is used to integrate recent technical advances in multiple fields with our highly translational research. In particular, cutting-edge imaging techniques such as MRI, PET and ultrasound are used to expedite research by providing accurate measures of novel therapies against cardiovascular disease and cancer.

Education

B.S. in Biochemistry from Louisiana State University in 1982

Ph.D. in Biochemistry from Louisiana State University in 1987

Post-Doc Baylor College of Medicine, Houston, TX/NIH/Dept. of Cell Biology from 1987-91

Our research has impact in: 1) uncovering disease mechanisms, 2) evaluating novel therapies, and 3) developing new imaging methods for diagnostics.

Brent A. French, Ph.D. Professor of Biomedical Engineering

Research Interests

Targeted Drug and Gene Delivery 2020

Biomedical Imaging

Tissue Engineering and Biomaterials

Cardiovascular Disease

Selected Publications

Implications of scar structure and mechanics for post-infarction cardiac repair and regeneration. Exp Cell Res. 376(1):98-103, 2019 French BA, Holmes JW Yet another subheading level

The myocardial infarct-exacerbating effect of cell-free DNA is mediated by the high-mobility group box 1-receptor for advanced glycation end products-Toll-like receptor 9 pathway. J Thorac Cardiovasc Surg. 157(6):2256-2269, 2019 Tian Y, Charles EJ, Yan Z, Wu D, French BA, Kron IL, Yang Z

Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. J Control Release. 28(220 Pt A):556-67, 2015. Dasa SS, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L, Klibanov AL, French BA, Kelly KA.

Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling. J Gene Med. 2012 Konkalmatt PR, Wang F, Piras BA, Xu Y, O'Connor DM, Beyers RJ, Epstein FH, Annex BH, Hossack JA, French BA

Robust cardiomyocyte-specific gene expression following systemic injection of AAV: In vivo gene delivery follows a Poisson distribution. Gene Therapy 18(1):43-52, 2011. Prasad K.M.R., Xu Y., Yang Z., Acton S.T., French B.A.

Brett A. French, Ph.D.

About

Education

Research Interests

Selected Publications

Related News Component

UVA's Exploration of New Frontier in Cancer Research Nets $12M Award

Engineering for Good: Clean Water for All - Courtney Hill

UVA's Exploration of New Frontier in Cancer Research Nets $12M Award